Abstract
Engineering of antibodies specific for tumor-associated antigens provides great flexibility in improving their properties for eventual use in the clinic, for the detection of cancer, or as a therapeutic. In some instances, murine monoclonal antibodies (MAbs) have been identified with innate biological anti-tumor activity. Production of chimeric or humanized (CDR-grafted) antibodies lowers the immunogenicity of murine MAbs, a necessary modification if repeat administration is desired (1,2). Chimerization or humanization can also increase the ability of murine MAbs to interact with the human immune system. The anti-lymphoma and anti-breast cancer antibodies Rituxan™ (Rituximab) and Herceptin™ (Trastuzumab) are robust examples of this path to a clinically useful reagent (3,4). Production of chimeric or humanized antibodies with Fc regions of a suitable subclass allows engagement of human host immune responses (complement activation, antibody-dependent cellular cytotoxity). Many anti-tumor MAbs, however, must be further “armed” in some fashion in order to be useful as therapeutics. Alternate approaches, described in detail elsewhere in this volume, include fusion of antibodies to toxins or cytotoxic proteins such as ribonuclease, production of bispecific antibodies for recruitment of effector T cells, or direct activation of T cells through chimeric T-cell receptors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Morrison S. L., Johnson J. M., Herzenberg L. A., and Oi V. T. (1984). Chimeric antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 81, 6851–6855.
Jones P. T., Dear P. H., Foote J., Neuberger M. S., and Winter G. (1986). Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522–525.
Grillo-Lopez A. J., White C. A., Varns C., Shen D., Wei A., Mcclure A., and Dallaire B. K. (1999). Overview of the clinical developent of rituximab: First monoclonal antibody approved for the treatment of lymphoma. Seminars in Oncol. 26, 66–73.
Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C. C., Dantis L., et al. (1996). Phase II study of weekly intravenous recombinant humanized Anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast. J. Clin. Oncol. 14, 737–744.
Junghans R. P. (1997). Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol. Res. 16, 29–57.
Bird R. E., Hardman K. D., Jacobson J. W., Johnson S., Kaufman B. M., Lee S. M., et al. (1988). Single-chain antigen-binding proteins. Science 242, 423–426.
Huston J. S., George A. J. T., Adams G. P., Stafford W. F., Jamar F., Tsai M.-S., et al. (1996). Single-chain Fv radioimmunotargeting. Q. J. Nuc. Med. 40, 320–323.
Begent R. H. J., Verhaar M. J., Chester K. A., Casey J. L., Green A. J., Napier M. P, et al. (1996). Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nature Med. 2, 979–984.
Larson S. M., El-Shirbiny A. M., Divgi C. R., Sgouros G., Finn R. D., Tschmelitsch J., et al. (1997). Single chain antigen binding protein (sFv CC49). First human studies in colorectal carcinoma metastatic to liver. Cancer 80, 2458–2468.
Holliger P., Prospero T., and Winter G. (1993). “Diabodies”: Small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 90, 6444–6448.
Wu A. M., Chen W., Raubitschek A. A., Williams L. E., Fischer R., Hu S., et al. (1996). Tumor localization of anti-CEA single chain Fvs: Improved targeting by non-covalent dimers. Immunotechnology 2, 21–36.
Adams G. P., Schier R., McCall A. M., Crawford R. S., Wolf E. J., Weiner L. M., and Marks J. D. (1998). Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br. J. Cancer 77, 1405–1412.
Pavlinkova G., Beresford G. W., Booth B. J. M., Batra S. K., and Colcher D. (1999). Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. J. Nucl. Med. 40, 1536–1546.
Viti F., Tarli L., Giovannoni L., Zardi L., and Neri D. (1999). Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res. 59, 347–352.
Hu S., Shively L., Raubitschek A. A., Sherman M., Williams L. E., Wong J. Y. C., et al. (1996). Minibody: A novel engineered anti-CEA antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56, 3055–3061.
Pack P. and Pluckthun A. (1992). Miniantibodies: Use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with avidity in Escherichia coli. Biochemistry 31, 1579–1584.
Kostelny S. A., Cole M. S., and Tso J. Y. (1992). Formation of a bispecific antibody by the use of leucine zippers. J. Immunol. 148, 1547–1553.
Ridgway J. B., Presta L. G., and Carter P. (1996). “Knobs-into-holes” engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9, 617–621.
Dübel S., Breitling F., Kontermann R., Schmidt T., Skerra A., and Little M. (1995). Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv). J. Immunol. Methods 178, 201–209.
Shively J. E. and Beatty J. D. (1985). CEA-related antigens: molecular biology and clinical significance. Crit. Rev. Oncol. Hematol. 2, 355–399.
Hammarström S. (1999). The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin. in Cancer Biol. 9, 67–81.
Goldenberg D. M. and Larson S. M. (1992). Radioimmunodetection in cancer identification. J. Nucl. Med. 33, 803–814.
Goldenberg D. M. (1993). Monoclonal antibodies in cancer detection and therapy. Am. J. Med. 94, 297–312.
Buchegger F., Haskell C. M., Schreyer M., Scazziga B. R., Randin S., Carrel S., and Mach J. P. (1983). Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice. J. Exp. Med. 158, 413–427.
Moffat F. L. Jr., Pinsky C. M., Hammershaimb L., Petrelli N. J., Patt Y. Z., Whaley F. S., and Goldenberg D. M. (1996). Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab′ antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. J. Clin. Oncol. 14, 2295–2305.
Wu A. M. and Yazaki P. J. (2000). Designer genes: recombinant antibody fragments for biological imaging. Q. J. Nucl. Med. 44, 268–283.
Wu A. M., Yazaki P. J., Tsai S., Nguyen K., Anderson A.-L., McCarthy D. W., et al. (2000). High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts using a copper-64 labeled engineered antibody fragment. Proc. Natl. Acad. Sci. USA 97, 8495–8500.
Yazaki P. J., Shively L., Clark C., Cheung C.-W., Le W., Szpikowska B., et al. (2001). Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications. J. Immunol. Methods 253, 195–208.
Chirgwin J. M., Przybyla A. E., MacDonald R. J., and Rutter W. J. (1979). Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18, 5294.
Bebbington C. R. (1991). Expression of antibody genes in nonlymphoid mammalian cells. Methods Companion Methods Enzymol. 2, 136–145.
Bebbington C. R., Renner G., Thomson S., King D., Abrams D., and Yarranton G. T. (1992). High-level expresion of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Bio/Technology 10, 169–175.
You Y. H., Hefta L. J., Yazaki P. J., Wu A. M., and Shively J. E. (1998). Expression, purification, and characterization of a two domain carcinoembryonic antigen minigene (N-A3) in Pichia Pastoris. The essential role of the N-domain. Anticancer Res. 18, 3193–3202.
Laemmli U. K. (1970). Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 227, 680–685.
Towbin H., Staehlin T., and Gordon J. (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76, 4350–4354.
Gagnon P. Purification Tools for Monoclonal Antibodies, Validated Biosystems, Inc., Tuscon, AZ, 1996.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc.
About this protocol
Cite this protocol
Yazaki, P.J., Wu, A.M. (2003). Construction and Characterization of Minibodies for Imaging and Therapy of Colorectal Carcinomas. In: Welschof, M., Krauss, J. (eds) Recombinant Antibodies for Cancer Therapy. Methods in Molecular Biology™, vol 207. Humana Press. https://doi.org/10.1385/1-59259-334-8:351
Download citation
DOI: https://doi.org/10.1385/1-59259-334-8:351
Publisher Name: Humana Press
Print ISBN: 978-0-89603-918-6
Online ISBN: 978-1-59259-334-7
eBook Packages: Springer Protocols